Close Menu

NOTCH1

Deleterious NOTCH mutations may predict more favorable immune checkpoint responses in lung cancer patients without EGFR or ALK mutations.

A collection of biomarker- and genomic testing-driven precision oncology research presented at the European Society of Medical Oncology Congress.

The partners are working together to advance tests that will identify which cancer patients have Notch activating mutations and fusions.